{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:57:37Z","timestamp":1785419857316,"version":"3.56.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2023,5,20]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Opsoclonus\u2013myoclonus\u2013ataxia syndrome (OMAS) is characterised by the combination of opsoclonus and arrhythmic action myoclonus with axial ataxia and dysarthria. In adults, a majority are paraneoplastic secondary to solid organ tumours and could harbour antibodies against intracellular epitopes; however, certain proportions have detectable antibodies to various neuronal cell surface antigens. Anti-N-methyl-D-aspartate (NMDAR) antibodies and ovarian teratomas have been implicated in OMAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Report of two cases and review of literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two middle-aged women presented with subacute-onset, rapidly progressive OMAS and behavioural changes consistent with psychosis. The first patient had detectable antibodies to NMDAR in the cerebrospinal fluid (CSF) alone. Evaluation for ovarian teratoma was negative. The second patient had no detectable antibodies in serum or CSF; however, she had an underlying ovarian teratoma. Patient A was treated with pulse steroids, therapeutic plasma exchange (TPE) followed by bortezomib (BOR) and dexamethasone, while patient B was treated with steroids, TPE followed by surgical resection of ovarian teratoma. Both patients had favourable outcomes and were asymptomatic at the 6 monthly follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With coexistent neuropsychiatric manifestations, OMAS can be considered a distinct entity of autoimmune encephalitis, pathogenesis being immune activation against known\/unknown neuronal cell surface antigens. The observation of absence of anti-NMDAR antibody in patients with teratoma-associated OMAS and vice versa is intriguing. Further research on the potential role of ovarian teratoma in evoking neuronal autoimmunity and its targets is required. The management challenge in both cases including the potential use of BOR has been highlighted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2023-000414","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T15:02:18Z","timestamp":1687532538000},"page":"e000414","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Opsoclonus myoclonus ataxia syndrome, ovarian teratoma and anti-NMDAR antibody: an \u2018unresolved\u2019 mystery"],"prefix":"10.1136","volume":"5","author":[{"given":"Angel T","family":"Miraclin","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Mathai","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Sivadasan","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munagapati","family":"Christina","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail Ruth","family":"Gojer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Milton","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Jude Prakash","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit N","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-1808","authenticated-orcid":false,"given":"Appaswamy Thirumal","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjith","family":"Aaron","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Christian Medical College Vellore, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2025072811384655000_5.1.e000414.1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2011-000017"},{"key":"2025072811384655000_5.1.e000414.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(01)00564-0"},{"key":"2025072811384655000_5.1.e000414.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410050502"},{"key":"2025072811384655000_5.1.e000414.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.03.013"},{"key":"2025072811384655000_5.1.e000414.5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jamaneurol.2015.4607","article-title":"Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies","volume":"73","author":"Armangu\u00e9","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025072811384655000_5.1.e000414.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.9.1526"},{"key":"2025072811384655000_5.1.e000414.7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22941"},{"key":"2025072811384655000_5.1.e000414.8","first-page":"64","article-title":"Opsoclonus-myoclonus syndrome","volume":"69","author":"Arroyo","year":"2009","journal-title":"Medicina (Mex)"},{"key":"2025072811384655000_5.1.e000414.9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00415-018-9138-7","article-title":"Update on opsoclonus-myoclonus syndrome in adults","volume":"266","author":"Oh","year":"2019","journal-title":"J Neurol"},{"key":"2025072811384655000_5.1.e000414.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003536"},{"key":"2025072811384655000_5.1.e000414.11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/acn3.557","article-title":"Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis","volume":"5","author":"Shin","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2025072811384655000_5.1.e000414.12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fneur.2020.00188","article-title":"Early bortezomib therapy for refractory anti-NMDA receptor encephalitis","volume":"11","author":"Turnbull","year":"2020","journal-title":"Front Neurol"},{"key":"2025072811384655000_5.1.e000414.13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14740\/jcgo715","article-title":"Ovarian teratoma and N-methyl-D-aspartate receptor autoimmune encephalitis: insights into imaging diagnosis of teratoma and timing of surgery","volume":"10","author":"Thiyagarajan","year":"2021","journal-title":"J Clin Gynecol Obstet"},{"key":"2025072811384655000_5.1.e000414.14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.23917","article-title":"A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma","volume":"75","author":"Armangue","year":"2014","journal-title":"Ann Neurol"},{"key":"2025072811384655000_5.1.e000414.15","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.166"},{"key":"2025072811384655000_5.1.e000414.16","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.299"},{"key":"2025072811384655000_5.1.e000414.17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.pediatrneurol.2015.07.010","article-title":"Pediatric opsoclonus-myoclonus-ataxia syndrome associated with anti-N-methyl-D-aspartate receptor encephalitis","volume":"53","author":"Player","year":"2015","journal-title":"Pediatr Neurol"},{"key":"2025072811384655000_5.1.e000414.18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.23917","article-title":"A novel treatment-responsive encephalitis with frequent opsoclonus and Teratoma","volume":"75","author":"Armangue","year":"2014","journal-title":"Ann Neurol"},{"key":"2025072811384655000_5.1.e000414.19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu142"},{"key":"2025072811384655000_5.1.e000414.20","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e31824a1de2"},{"key":"2025072811384655000_5.1.e000414.21","doi-asserted-by":"publisher","DOI":"10.1159\/000353982"},{"key":"2025072811384655000_5.1.e000414.22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaneurol.2014.488","article-title":"Abnormal neurons in teratomas in NMDAR encephalitis","volume":"71","author":"Day","year":"2014","journal-title":"JAMA Neurol"},{"key":"2025072811384655000_5.1.e000414.23","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0693-7","article-title":"Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis","volume":"7","author":"Chefdeville","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2025072811384655000_5.1.e000414.24","unstructured":"Frontiers . Early bortezomib therapy for refractory anti-NMDA receptor encephalitis. Neurology. Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.00188\/full [Accessed 3 Jul 2020]."},{"key":"2025072811384655000_5.1.e000414.25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2023-000414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:38:53Z","timestamp":1753727933000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2023-000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,23]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjno-2023-000414"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2023-000414","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}